Guillaume Grs

🌟Challenges in Defining Clinical CR to Systemic Therapy in MIBC🌟 @EORTC #STARBURST project 🖋️ Alexandra Masson-Lecomte @AFUrology, Guillaume Grisay, @vandamme_jvd,  @Achard_Verane  , @LAUrology_NL, @robert_huddart, @frasor86, @LDyrskjot, Yves Allory @institut_curie,…

🚨 Defining clinical response to neoadjuvant CT in bladder is crucial to offer bladder-sparing strategies in complete or near cplt responders ! EORTC Starbust-1 will launch soon @amassonlecomte @EORTC @y_loriot @BertrandTOMBAL @Achard_Verane @vandamme_jvd sciencedirect.com/science/articl…

Check out our free 20-minute webinar with a multidisciplinary panel of experts discussing the most recent data from clinical trials, treatment (de)escalation, and the role of ultra-low PSA in #mHSPC Register for free at library.mirrorsmed.org/?utm_code=SoMe… @vandamme_jvd @OncoAlert #GU…

Thank you #EMUC24 for giving me the opportunity to talk about the management of mCRPC patients

mHSPC patient with profound PSA response : panel would propose de-escalation therapy ! #EMUC2024 @BertrandTOMBAL @Silke_Gillessen @fabioturco92

Nice talk by Dr Masson-Lecomte on the importance of defining the response to NAT, as well as the importance of multimodal assessment. Question will be answered by the EORTC2418 - ‘STARBURST’ study !#EORTC #EMUC24 @y_loriot @Achard_Verane @vandamme_jvd @GGrisay @BertrandTOMBAL

Congrats to @vandamme_jvd @GIZZIMarcoMd for this nice poster #EMUC24 @BertrandTOMBAL

#NOVEMBREAUMASCULIN - Conférence de presse en cours pour présenter cette 2e édition du Mois de la Santé Masculine 🔵 @delataillealex #Santemasculine #BrisonsLesTabous 🚹

OH LA PHOTO

🚨 Excellent talk on germline testing in PC by Heather H. Cheng🚨 ✅ It matters for patients AND families ✅ Germline alt. are FREQUENT and have consequences for patients 🧬Tumor-only sequencing failed to detect > 20% of pathogenic variants ⚠ @APCCC_Lugano @OncoAlert #APCCC24

95% of @APCCC_Lugano Panellists DO NOT recommend ARPI switch for mCRPC. Yet why do investigators (many of them Panellists) and FDA approve this as control arm for trials?? “Unethical” says @AnthonyMJoshua from the floor, as did @VPrasadMDMPH on GU Cast @gu_onc #APCCC24

🤔 How to choose a 1st line therapy in mCRPC patients nowadays ? 🚨 ➤ Some excellent suggestions from @ChrisSweens1 at @APCCC_Lugano @OncoAlert #APCCC24

Now more than ever, it is important to propose de-escalation strategies. EORTC 2238 "De-Escalate" will address the specific question of intermittent therapy in these mHSPC patients ! @BertrandTOMBAL @Silke_Gillessen @fabioturco92 @APCCC_Lugano @EORTC @OncoAlert

Very nice take on doublet vs triplet therapy in mHSPC patients by @Prof_Nick_James at @APCCC_Lugano #APCCC24 #OncoAlert

❓ Patients with rising PSA post-RP & PSAdt <1 y OR ISUP 4-5 and ≥1 risk factor : ➤ 37% panelists would WAIT for PSMA-PET ➤ What happened to salvage RT to prostate bed ? 🤔 @APCCC_Lugano @APCCC24 @OncoAlert

Growing body of evidence suggests that patients with high-risk BCR should be managed with ARpI monotherapy. Side effects are manageable. the sooner the better ! Neil Shore @APCCC_Lugano @APCCC24 @OncoAlert